



THE 17TH INTERNATIONAL CONFERENCE ON
**ADVANCED TECHNOLOGIES &
TREATMENTS FOR DIABETES**

6-9 MARCH 2024
FLORENCE & ONLINE

(*Subject to change)

SCIENTIFIC PROGRAM*

Wednesday, 6 March, 2024

13:00-14:15	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)					
14:30-14:40	Break to Change Halls					
14:40-16:10	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	#dedoc° Symposium WHAT WE WISH YOU KNEW – AND WHY (14:40 – 16:00)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)
16:10-16:20	Break to Change Halls					
16:20-17:50	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)					
18:00-18:40	OPENING SESSION <u>Moshe Phillips</u> - Opening Remarks <u>Melanie Davies</u> – A new era in the management of T2DM and obesity – Scanning what's on the horizon					
18:40-19:00	OPENING EVENT					
19:00-20:00	NETWORKING RECEPTION (in the Exhibition Area)					

Thursday, 7 March, 2024

08:00-09:00	HOT FROM THE OVEN							
	<p><u>Jennifer Sherr</u> - A more comprehensive metabolic picture: Pairing continuous glucose and ketone sensors to detect early DKA</p> <p><u>Julio Rosenstock</u> - Update on the SURPASS-6 trial testing Tirzepatide vs. Insulin Lispro to advance Basal Insulin Therapy: Emerging horizons beyond Basal-Bolus Insulin Therapy in T2DM</p> <p><u>Michael Bergman</u> - ONLINE FIRST RELEASE on: IDF position statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycemia and type 2 diabetes</p>							
09:00-10:00	PLENARY 1 - TOWARD THE FUTURE							
	<p><u>Moshe Phillip</u> - From dream to reality - The Automated Insulin Delivery (AID) system</p> <p><u>Boris Kovatchev</u> - Neural-Net artificial pancreas</p> <p><u>Camillo Ricordi</u> - From the first-in-human success in stem cell derived Islet Transplantation to a cure for all patients with diabetes: Challenges, requirements, and possible solutions</p>							
10:00-10:30	COFFEE BREAK, EXHIBITION & E-POSTERS							
10:30-12:00	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)							
12:00-13:00	LUNCH BREAK, EXHIBITION & E-POSTERS							
13:00-14:30	PARALLEL SESSION 1 AUTOMATED INSULIN DELIVERY IN TYPE 1 AND TYPE 2 DIABETES	PARALLEL SESSION 2 CGM DIABETES QUALITY MEASURES	PARALLEL SESSION 3 HYPOLYCEMIA - ANY PROGRESS?	PARALLEL INDUSTRY SYMPOSIUM <small>(not included in the main event CME/CPD credit)</small>	JDRF - PARALLEL SESSION 4 INTERNATIONAL CONSENSUS MONITORING GUIDANCE FOR PRESYMPOTOMATIC (EARLY STAGE) TYPE 1 DIABETES	PARALLEL SESSION 5 INTERVENTION AND PREVENTION OF TYPE 1 DIABETES	PARALLEL SESSION 6 COPING WITH OBESITY	ORALS 1
	<p>Anders Carlson - Use of AID in patients with type 2 diabetes</p> <p>Roman Hovorka - Fully closed-loop in type 1 and type 2 diabetes</p> <p>Bruce Bode - Management of glucose in the hospital with AID systems</p> <p>May Ng - Bringing technology to diabetes care - From evidence to policy</p>	<p>Irl Hirsch - What has the GMI taught us about A1C?</p> <p>Elisabeth Selvin - Should A1C still be a diagnostic criterion for diabetes in 2024?</p> <p>Gregg Simonson - CGM (GMI/TIR) as diabetes quality metrics</p> <p>Guido Freckmann - International standard for evaluation of CGM systems: Approach of the IFCC</p>	<p>Stephanie Amiel - CGM detection of hypoglycemia in diabetes management</p> <p>Simon Heller - Should the classification of hypoglycemia be updated?</p> <p>Pratik Choudhary - Implication of HypoMETRICS for reporting hypoglycemia in clinical trials</p> <p>Bastiaan de Galan - Impaired awareness of hypoglycemia</p>		<p>Moshe Phillip - The rationale for consensus monitoring guidance for presymptomatic type 1 diabetes</p> <p>Linda DiMeglio - Summary of the consensus monitoring guidance for presymptomatic type 1 diabetes</p> <p>Kirstine Bell - Implications for research and clinical care</p> <p>Emanuele Bosi - Population screening for type 1 diabetes is now a reality: An update from Italy</p>	<p>Teresa Rodriguez-Calvo - Role of viruses in pathogenesis of type 1 diabetes</p> <p>Rohit Kulkarni - Targeting mRNA modifications to counter type 1 diabetes</p> <p>Roberto Mallone - Benign autoimmunity & progression to type 1 diabetes</p> <p>Desmond Schatz - Enhancing our understanding of why type 1 diabetes develops. Lessons learned from organ donors</p>	<p>Emma Wilmot - Technology-supported behavior intervention in type 2 diabetes</p> <p>Max Nieuwdorp - A balanced view on microbiome in obesity</p> <p>Luca Busetto - Will new pharmacological treatment for obesity and early diabetes replace bariatric surgery?</p> <p>Primož Kotnik - Managing severe obesity in pediatric population</p>	

14:30-14:40	Break to Change Halls							
14:40-16:10	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)							
16:10-16:40	COFFEE BREAK, EXHIBITION & E-POSTERS							
16:40-18:10	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL SESSION 7 STANDARDIZATION OF PROS	ORALS 2	PARALLEL SESSION 8 ROLE OF TECHNOLOGY IN NORMAL HEALTHY AND IN GDM PREGNANCY	PARALLEL SESSION 9 THE EFFECT OF DIABETES ON BRAIN HEALTH	PARALLEL SESSION 10 HYBRID CLOSED-LOOP FOR TYPE 2 DIABETES - HURDLES AND BENEFITS	PARALLEL SESSION 11 ACCESSIBILITY AND DISPARITIES OF DIABETES THERAPY	ORALS 3
	<p>Oliver Schnell - What PROs mean in routine clinical care</p> <p>Katharine Barnard-Kelly - Consensus statement summary, navigating the maze of PROs</p> <p>Mary Murphy - What inclusion of quality PRO assessment in clinical trials means to people with diabetes</p> <p>Alon Liberman – Real world data from type 1 diabetes clinics</p>		<p>Celeste Durnwald – Can CGM replace the oral glucose tolerance test for diagnosis of gestational diabetes?</p> <p>Eleanor Scott - CGM glucose trajectories associated with large and small for gestational age birthweight</p> <p>Helen Murphy – Should everyone with type 1 diabetes be offered closed-loop during pregnancy?</p> <p>Yariv Yoge - Should all women with diabetes in pregnancy undergo induction of labor at 38 weeks of gestation?</p>	<p>Mark Strachan - Update on diabetes-associated cognitive dysfunction</p> <p>Tali Cukierman-Yaffe - Diagnosis & monitoring of brain health in people with diabetes</p> <p>Hertzl Gerstein - Brain aging in people with diabetes - Possible intervention</p> <p>David Tanne - Novel approaches and the role of technology in treating brain aging in people with diabetes</p>	<p>Yves Reznik - Closed-loop as home care for type 2 diabetes: The Close study</p> <p>Charlotte Boughton - Cumulated experience with CamAPS in type 2 diabetes</p> <p>Gregory Forlenza - Real-world data on hybrid closed-loop (HCL) in type 2 diabetes</p> <p>Anne Peters - Pod use for closed-loop in type 2 diabetes</p>	<p>Lori Laffel - Interventions to reduce health disparities in diabetes device use</p> <p>V Mohan – Innovating to use existing technologies under resourced settings</p> <p>Partha Kar - Widening clinical use of diabetes tech in the UK</p> <p>Stuart Weinzimer - Strategies to facilitate technology use in disadvantaged youth with diabetes</p> <p>Ananta Addala - Solutions for equity: A call to action</p>		

Friday, 8 March, 2024

12:30-13:30	LUNCH BREAK, EXHIBITION & E-POSTERS
13:30-15:00	PLENARY 2 ATTD YEARBOOK SESSION
	<p><u>Klemen Dovc</u> - Continuous and intermittent glucose monitoring</p> <p><u>Rayhan A. Lal</u> - Insulin delivery hardware: pumps and pens</p> <p><u>Lutz Heinemann</u> - New insulins, biosimilars and insulin therapy</p> <p><u>Mark Clements</u> - Closed-loop, artificial intelligence-based decision support systems and data science</p> <p><u>Mark Clements</u> - Using digital health technology to prevent and treat diabetes</p> <p><u>Jennifer M. Yamamoto</u> - Technology and pregnancy</p> <p><u>David M. Maahs</u> - Diabetes technology and therapy in the pediatric age group</p> <p><u>Dessi P. Zaharieva</u> - Advances in exercise and nutrition as therapy in diabetes</p> <p><u>Thomas W. Martens</u> - Primary care and diabetes technologies and treatments</p> <p><u>Medha Munshi</u> - Use of technologies at the advanced age</p> <p><u>Ananta Addala</u> - Diabetes technology in the "real world": Expanding access and addressing disparities</p> <p><u>Alon Liberman</u> - Diabetes technology and the human factor</p> <p><u>Desmond Schatz</u> - Immune interventions and restorative therapies in type 1 diabetes</p> <p><u>Viral N. Shah</u> - Obesity, NAFLD/NASH and diabetes</p> <p><u>Satish K. Garg</u> - Virtual clinics for diabetes care</p> <p><u>Satish K. Garg</u> - New medications for the treatment of diabetes</p>
15:00-15:15	Break
15:15-16:45	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)
16:45-17:15	COFFEE BREAK, EXHIBITION & E-POSTERS

17:15-18:45	PARALLEL SESSION 17 OBESITY IN TYPE 1 DIABETES	PARALLEL SESSION 18 AUTOMATED INSULIN DELIVERY IN CHILDREN	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL SESSION 19 SELF MANAGEMENT OF DIABETES (17:15-18:05)	PARALLEL SESSION 20 CGM GUIDED PRECISION DIABETES MANAGEMENT	PARALLEL SESSION 21 INTEROPERABILITY OF DIABETES TECHNOLOGY	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	ORALS 5
	Satish Garg - Management options for treating obesity in type 1 diabetes patients Jeremy Pettus - Insulin resistance in type 1 diabetes: An underappreciated problem Kirsten Nørgaard - Effects of GLP1 in type 1 diabetes Victor Gerdes - Bariatric surgery in diabetes	Revital Nimri - Maximizing glycemic control with automated insulin delivery in young children Thomas Danne – Worldwide progress achieving treatment targets in children with type 1 diabetes Ivana Rabbone - Technology in the changing management of diabetes in children Nataša Bratina - Data on diabetes treatment in children below the age of six		Mark Clements – Just in time adaptive interventions: The new technology to "hack" diabetes self-management behavior John Leth - The potential of open-source software in diabetes research Heiko Peuscher - A survey on existing open-source projects in diabetes simulation	Tara Ettestad - CGM Guided Nutrition Michael Riddell - CGM guided exercise Thomas Martens – CGM guided insulin management Darja Šmigoc Schweiger - Guided management of diabetes in female	David Klonoff – Interoperability of diabetes technology Academic view Alexander Olbrechts - Interoperability of diabetes technology - A company's view Johan Jendle - Interoperability of diabetes technology - Regulatory hurdle Tim Street – Interoperability of diabetes technology - Patient's view		
18:45-18:55								
18:55-20:25	IGNITE START-UP NETWORKING EVENT (not included in the main event CME/CPD credit)				ATTD PARTNER EVENT (not included in the main event CME/CPD credit) (19:15 – 21:30)			

Saturday, 9 March, 2024

13:45-15:15	PARALLEL SESSION 34 OBESITY AND TYPE 2 DIABETES	PARALLEL SESSION 35 DIABETES IN ITALY	ORALS 10	ISPAD/ATTD - PARALLEL SESSION 36 DIABETES TECHNOLOGY IN LOWER INCOME COUNTRIES	PARALLEL SESSION 37 DTECH SYMPOSIUM - DIABETES IN INDIA	PARALLEL SESSION 38 SARCOPENIA, FRAILTY AND DIABETES	ORALS 11
	<p><u>Antonio Ceriello</u> - Weight and glycemic variability: Bad companions for CVD development in diabetes</p> <p><u>Kamlesh Khunti</u> - Early intervention for type 2 diabetes in primary care</p> <p><u>Barbara McGowan</u> - Medical therapies for treatment of obesity</p> <p><u>Jernej Kovac</u> - Genetic background of obesity</p>	<p><u>Marco Marigliano</u> - Relationships between insulin delivery system, CGM satisfaction and glucometrics</p> <p><u>Andrea Scaramuzza</u> - Real-world data in very young AHCL users - Comparison among different systems</p> <p><u>Nicola Minuto</u> - Sick days management using AHCL systems in pediatrics: What to do when the algorithm is not enough</p> <p><u>Sergio di Molfetta</u> - CGM in type 2 diabetes patients: From professional use to experiences in patients not insulin treated</p>		<p><u>Renza Scibilia</u> – Type 1 diabetes global index and overview of diabetes technology present and future in lower income countries</p> <p><u>Thereza Piloya-Were</u> - Impact of CGM in East Africa, research and translation</p> <p><u>Hamidah Nabakka</u> - Diabetes advocate perspective on diabetes technology in low-income countries</p>	<p><u>Banshi Saboo</u> - Welcome and introduction to Dtech symposium</p> <p><u>Shashank Joshi</u> - Artificial intelligence in diabetes care</p> <p><u>Jothydev Kesavadev</u> - 25 years of telemedicine vs. conventional care in diabetes: Assessing vascular complications and quality of life</p> <p><u>Manoj Chawla</u> - Optimizing real time CGM in self-pay markets</p> <p><u>Amit Gupta</u> - Challenges and opportunities in digital diabetes care in India</p> <p><u>Mithun Bhartia</u> - Diabetes and sex life – The role of technology to improve quality of life</p> <p><u>Rakesh Parikh</u>: Artificial Intelligence in the management of diabetes</p>	<p><u>Alan Sinclair</u> - Diabetes, sarcopenia and frailty: Interrelationships and clinical importance</p> <p><u>Leocadio Rodríguez Mañas</u> - Current treatment options for sarcopenia in the context of frail older people with diabetes</p> <p><u>Tali Cukierman-Yaffe</u> - How to measure and monitor sarcopenia and frailty</p>	

15:15-15:25	Break to Change Halls
15:25-16:25	PLENARY 3 CURE OF DIABETES
	<u>Michael Haller</u> - Cost effectiveness of immune therapies in preserving beta cell function – Real world applications <u>Jay Skyler</u> - Stem cell approaches to type 1 diabetes <u>Michael Rickels</u> - Islet cell therapy vs. closed loop insulin delivery for type 1 diabetes
16:25-17:00	CLOSING REMARKS
17:00	FAREWELL REFRESHMENTS